cervical cancer
Oncology · 2007–2025
11decisions
5medicines
6carried consumer input
17individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Treatment of high-risk, locally advanced cervical cancer (FIGO 2014 Stage IB2-IIB node-positive or Stage III-IVA) in combination with concurrent… | Mar 2025 | Recommended with restriction | input received Rare Cancers Australia · Medical Oncology Group |
| bevacizumab Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced… | Mar 2024 | Recommended with restriction | 1 individuals |
| pembrolizumab Treatment of persistent, recurrent, or metastatic (Stage IVB) squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma of the cervix in patients… | Nov 2022 | Recommended with restriction | input received Rare Cancers Australia · Medical Oncology Group |
| topotecan Treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent therapy; small cell lung carcinoma after failure of first-line… | Jul 2020 | Recommended with restriction | input received Lung Foundation Australia |
| bevacizumab Treatment of persistent, recurrent or metastatic cervical cancer not amenable to curative treatment with surgery and/or radiation, in combination with… | Mar 2016 | Recommended with restriction | input received Medical Oncology Group · Rare Cancers Australia |
| bevacizumab Treatment of persistent, recurrent or metastatic cervical cancer not amenable to curative treatment with surgery and/or radiation therapy, in combination with… | Nov 2015 | Not recommended | 16 individuals |
| human papillomavirus (HPV) types 16/18 vaccine Prophylactic vaccination of females aged 12-13 years against cervical cancer and precancerous lesions associated with HPV-16 and HPV-18, using a 2-dose regimen… | Nov 2015 | Recommended | none received |
| human papillomavirus (Types 16 and 18) recombinant, AS04 adjuvanted vaccine prophylactic vaccination of 12 and 13 year old girls against cervical cancer and precancerous lesions associated with high risk human papillomavirus-types 16… | Jul 2007 | Recommended | no section in document |
| Human papillomavirus (Types 16 and 18) recombinant, AS04 adjuvanted vaccine Prophylactic vaccination of 12 and 13 year old girls (with a two-year catch up program for girls and women aged 13-26) against cervical cancer and precancerous… | Jul 2007 | Recommended | no section in document |
| Human Papillomavirus (Types 16 and 18) recombinant, AS04 adjuvanted vaccine Prophylactic vaccination of 12 and 13 year old girls (with a two-year catch up program for girls and women aged 13-26) against cervical cancer and precancerous… | Nov 2007 | Recommended | no section in document |
| Human Papillomavirus (Types 16 and 18) recombinant, AS04 adjuvanted vaccine Prophylactic vaccination of 12 and 13 year old girls (with a two-year catch up program for girls and women aged 13-26) against cervical cancer and precancerous… | Nov 2007 | Recommended | no section in document |
Who spoke
Medical Oncology Group · Rare Cancers Australia · Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.